## Dab/Tram (dabrafenib and trametinib)



Dab/Tram (dabrafenib and trametinib)	Dab/Tram (dabrafenib and trametinib)
PRELIMINARY SCORE	FINAL SCORE
CURATIVE	CURATIVE
	Overall Survival / Disease-Free Survival / Pathological Complete Response
NON-CURATIVE	
ORR	NON-CURATIVE
ADJUSTMENTS	Overall Survival
Quality of life	
Calling Commo	Progression-Free Survival
	Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate
Serious and disabling adverse effects	
More serious and disabling adverse events	Overall Response Rate / Duration of Response
observed	Overall Survival / Disease-Free Survival / Pathological Complete Response
Other adjustments	INFORMATION
	Tumour type: Thoracic Malignancies Therapeutic Indication: Advanced NSCLC with a BRAF V600 mutation Experimental Arm: Dab/Tram (dabrafenib and trametinib) Control Arm: Single arm



© 2023 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.